Monthly Archives: July 2010

Fussy Eaters – What’s Wrong with Biotech Food?

In the BBC News “Green Room,” Prof. Jonathan Jones wonders why there is such a fuss about biotechnology when it can help deliver a sustainable global food system. We can improve crop variety performance by both plant breeding (which gets better every year with new genetic methods), and by genetic modification (GM).  Ouch; yuck – GM. Did you recoil from those letters? Why? “I started making GM plants (petunias, as it happens) in 1983, working Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Adoptions of Genetically Engineered Corn, Soybeans, and Cotton by Farmers Are Up

Yesterday the USDA released a report stating that the adoptions of genetically engineered corn, soybeans, and cotton by farmers are up from this time last year. This just goes to show that when a farmer experiences the advantages that occur with GE seeds, they’ll use them again. The most commonly adopted traits so far are herbicide-tolerance and insect-resistance. The 14 million farmers worldwide using GE crops are mostly adopting them because of the economic advantages Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Final Notes from BIO's World Congress

On June 29 at BIO’s World Congress, Steen Riisgaard, CEO of Novozymes, and Stephen Tanda, Board Member of Royal DSM N.V., released a report from the World Economic Forum on The Future of Industrial Biorefineries. The report says that a biorefinery value chain could create revenue for agricultural inputs ($15 billion US), for biomass production ($89 billion), for biomass trading ($30 billion), for biorefining inputs ($10 billion), for biorefining fuels ($80 billion), for bioplastics ($6 Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

BIO Media Briefing Provides Update on Key Public Policy Issues

BIO hosted a media briefing on Wednesday, June 30th, with Jim Greenwood and Rachel King, Co-Founder and CEO of GlycoMimetics, Inc. and member of BIO’s Executive Committee. Jim and Rachel addressed the public policies under consideration by Congress, regulatory agencies and the courts which have the potential to impact the biotechnology industry.  Key discussion topics included implementation of health care reform (biosimilars, comparative effectiveness, Therapeutic Discovery Project Program, and Cures Acceleration Network), upcoming reauthorization of Read More >

Jim's Corner  |  Leave a comment  |  Email This Post